Bruker launches the iNTApharma platform
Original story from Bruker Corporation (MA, USA).
Bruker has launched iNTApharma, a label-free characterization platform that offers single-particle sensitivity for quantitative analysis of nanoscale bioparticles in native aqueous media.
The announcement was made at SLAS 2026 (MA, USA). According to Bruker, iNTApharma delivers size and concentration measurements within minutes, which supports research, therapy development and quality control workflows that require direct, native-state assessment of bio-nanoparticle populations without labeling or chemical modifications.
The iNTApharma system enables label-free, native characterization of vectors used in gene and cell therapy, and of lipid nanoparticles (LNPs) used in mRNA drug delivery. Quantitative characterization of bioparticles under native buffer conditions is increasingly important in areas such as extracellular vesicle research, adenovirus development, lentiviral vector analysis and LNP formulation for nucleic-acid delivery.
Native-state nanoparticle tracking analysis (NTA) is becoming a requirement in biopharma quality control, where assessment of particle size distributions, concentration levels and subpopulations is essential for process consistency. Demand is increasing for native-state characterization of viral vectors, LNPs and other nanoscale bioparticles due to the expansion of mRNA drug development, as well as cell and gene therapy development. iNTApharma supports analysis across diverse biological matrices through native-state, unlabeled measurements.
Optimized for bioparticles from 50–300 nanometers, iNTApharma provides measurement conditions suited for LNPs, lentiviral vectors, adenoviruses and extracellular vesicles. The system enables analysis of heterogeneous samples, including the resolution of subpopulations within mixtures. Its built-in well-plate reader functionality supports unattended and automated acquisition of datasets in standard laboratory workflows, without specialized sample preparation steps.
iNTApharma builds on optical measurement approaches developed at the Max-Planck-Institute for the Science of Light (Erlangen, Germany), which are also used in mass photometry. The platform translates advanced interferometric scattering detection methods into instrumentation for research, therapy development and QC environments.
Professor Vahid Sandoghdar, Director at the Max-Planck-Institute, said iNTApharma makes interferometric scattering microscopy capabilities broadly available and provides researchers with a tool that can deepen understanding of nanoscale bioparticles. Jürgen Srega, the President of the Bruker CALID Group, said the company is introducing a new tool that enables nanoparticle and bioparticle characterization for mRNA delivery, EV biology, gene therapy development and nanoscale formulation science.
Initial systems will be placed with early-access partners in the first half of 2026 to validate workflows under real-world conditions. Broader commercial availability is planned for H2 of 2026.
Bruker is enabling scientists and engineers to make post-genomic discoveries and develop new applications that improve the quality of human life. Bruker’s instruments and solutions enable scientists to explore life and materials at molecular, cellular, and microscopic levels. Bruker offers life science and diagnostics systems and solutions in preclinical imaging, clinical phenomics research, proteomics and multiomics, spatial and single-cell biology, functional structural and condensate biology, as well as in clinical microbiology, molecular diagnostics and therapeutic drug monitoring.
This article has been republished from the following materials. Material may have been edited for length and house style. For further information, please contact the cited source.
